Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 EGFR inhibitors, MHC expression and immune responses : Can EGFR inhibitors be used as immune response modifiers?

Literature DB >> 22720215

EGFR inhibitors, MHC expression and immune responses : Can EGFR inhibitors be used as immune response modifiers?

Abstract

A recent study from our laboratory demonstrated that epidermal growth factor receptor (EGFR) inhibitors (EGFRIs) augment the expression of class I and class II MHC molecules. This finding provides an additional mechanism through which EGFRIs may exert anti-tumor effects and supports the notion that EGFRIs may influence adaptive immune responses by altering immune gene expression.

Entities: Disease Gene

Year: 2012 PMID： 22720215 PMCID： PMC3376950 DOI： 10.4161/onci.1.1.18073

Source DB: PubMed Journal: Oncoimmunology ISSN： 2162-4011 Impact factor: 8.110

30 in total

Review 1. Photoimmunosuppression.

Authors: T Schwarz
Journal: Photodermatol Photoimmunol Photomed Date: 2002-06 Impact factor: 3.135

Review 2. "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy.

Authors: Federico Garrido; Teresa Cabrera; Natalia Aptsiauri
Journal: Int J Cancer Date: 2010-07-15 Impact factor: 7.396

Review 3. Strength of TCR-peptide/MHC interactions and in vivo T cell responses.

Authors: Emily Corse; Rachel A Gottschalk; James P Allison
Journal: J Immunol Date: 2011-05-01 Impact factor: 5.422

4. T cell receptor binding kinetics required for T cell activation depend on the density of cognate ligand on the antigen-presenting cell.

Authors: Pablo A González; Leandro J Carreño; Daniel Coombs; Jorge E Mora; Edith Palmieri; Byron Goldstein; Stanley G Nathenson; Alexis M Kalergis
Journal: Proc Natl Acad Sci U S A Date: 2005-03-16 Impact factor: 11.205

5. Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes.

Authors: Brian P Pollack; Bishu Sapkota; Todd V Cartee
Journal: Clin Cancer Res Date: 2011-05-17 Impact factor: 12.531

Review 6. EGFR signaling and drug discovery.

Authors: Georg Lurje; Heinz-Josef Lenz
Journal: Oncology Date: 2010-02-02 Impact factor: 2.935

7. Ultraviolet B radiation generated platelet-activating factor receptor agonist formation involves EGF-R-mediated reactive oxygen species.

Authors: Yongxue Yao; Jay E Wolverton; Qiwei Zhang; Gopal K Marathe; Mohammed Al-Hassani; Raymond L Konger; Jeffrey B Travers
Journal: J Immunol Date: 2009-03-01 Impact factor: 5.422

8. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation.

Authors: Francesca Mascia; Valentina Mariani; Giampiero Girolomoni; Saveria Pastore
Journal: Am J Pathol Date: 2003-07 Impact factor: 4.307

9. Interferon gamma-dependent transactivation of epidermal growth factor receptor.

Authors: Elena Burova; Konstantin Vassilenko; Victoria Dorosh; Ilya Gonchar; Nikolai Nikolsky
Journal: FEBS Lett Date: 2007-03-08 Impact factor: 4.124

10. Why targeted therapy hasn't worked in advanced cancer.

Authors: Jack L Arbiser
Journal: J Clin Invest Date: 2007-10 Impact factor: 14.808

15 in total

1. STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients.

Authors: Raghvendra M Srivastava; Sumita Trivedi; Fernando Concha-Benavente; Jie Hyun-Bae; Lin Wang; Raja R Seethala; Barton F Branstetter; Soldano Ferrone; Robert L Ferris
Journal: Cancer Immunol Res Date: 2015-05-13 Impact factor: 11.151

2. Inhibition of MHC-I by Brucella abortus is an early event during infection and involves EGFR pathway.

Authors: Lis N Velásquez; M Ayelén Milillo; M Victoria Delpino; Aldana Trotta; M Florencia Mercogliano; Roberto G Pozner; Roxana Schillaci; Patricia V Elizalde; Guillermo H Giambartolomei; Paula Barrionuevo
Journal: Immunol Cell Biol Date: 2016-11-29 Impact factor: 5.126

Review 3. Antitumour immunity regulated by aberrant ERBB family signalling.

Authors: Shogo Kumagai; Shohei Koyama; Hiroyoshi Nishikawa
Journal: Nat Rev Cancer Date: 2021-01-18 Impact factor: 60.716

4. Epigenetic changes in T-cell and monocyte signatures and production of neurotoxic cytokines in ALS patients.

Authors: Larry Lam; Lydia Chin; Ramesh C Halder; Bien Sagong; Sam Famenini; James Sayre; Dennis Montoya; Liudmilla Rubbi; Matteo Pellegrini; Milan Fiala
Journal: FASEB J Date: 2016-07-01 Impact factor: 5.191

Review 5. Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.

Authors: Zhong-Yi Dong; Si-Pei Wu; Ri-Qiang Liao; Shu-Mei Huang; Yi-Long Wu
Journal: Tumour Biol Date: 2016-01-16

6. Spatial Analysis and Clinical Significance of HLA Class-I and Class-II Subunit Expression in Non-Small Cell Lung Cancer.

Authors: Ila J Datar; Sacha C Hauc; Shruti Desai; Nicole Gianino; Brian Henick; Yuting Liu; Kostas Syrigos; David L Rimm; Paula Kavathas; Soldano Ferrone; Kurt A Schalper
Journal: Clin Cancer Res Date: 2021-02-18 Impact factor: 13.801